Heart Failure

New data showed that in-hospital mortality among patients with COVID-19 was nearly twice as high in those with a history of heart failure. A report on the data was the top story in cardiology last week.

Among patients hospitalized with COVID-19, in-hospital mortality risk was more substantial among those with HF history, according to new data published in Circulation: Heart Failure.

In a population-based cohort study, patients with diabetes taking an SGLT2 inhibitor had lower risk for hospitalization for HF compared with those taking a GLP-1 receptor agonist, researchers reported.

Aficamten, a novel selective cardiac myosin inhibitor, was associated with improvements in HF symptoms and hemodynamics at 10 weeks, according to a phase 2 study presented at the Heart Failure Society of America Annual Scientific Meeting.

Management of patients with HF with or without pulmonary artery pressure information derived from an implantable device (CardioMEMS, Abbott).

Empagliflozin (Jardiance, Boehringer Ingelheim-Eli Lilly) vs. placebo in patients with HFpEF.

The benefits of an intensive BP-lowering strategy to less than 120 mm Hg, as assessed in the SPRINT trial, were consistent even with the exclusion of HF-related events, according to data published in Hypertension.

Omecamtiv mecarbil was safe and effective compared with placebo in Black patients with HF with reduced ejection fraction, according to new data from GALACTIC-HF presented at the Heart Failure Society of America Annual Scientific Meeting.

Dapagliflozin improved symptoms and physical limitations in patients with HF with preserved ejection fraction, according to results from the PRESERVED-HF trial.

A mobile health intervention that included texts with feedback and updated personalized physical activity goals improved physical activity, quality of life and metabolomic profiling in patients with HF and diabetes, a speaker reported.